Weekend update, forward look First good day to all my Canadian chat room colleagues
A look back, sideways & forward....for .ONC.
As notable has pointed out, there is an increased frequency of pharma deals.
motivations plenety.
regarding Onc, creating a new co- therapy would create a patent extension. A great way to keep the existing in house product evaluation protected.
Of course many others, each of which has its own merrit & story.
Nice background & cool information, but what ir how does it effect oncolyitics biotech?
That is my only care & interest. So, my good friend notable. If/ when you post please expand the relevance to Onc directly.
I'm not suggesting your post do not relate to Onc, I'm just asking for that clarification.
Moving on to recent times.
I did listen to all of the Q4 update, Q &A and comments.
My opinion;
Nothing negative came out. However, IMHO there was something missing. Can't put my finger in it, just a feeling.
The expansion/ replacement with GCAR resurch ( utilizing previous PanCan precision promise) , for thec Pancreatice phase 3 , is very good news.
Yet it was underplayed in the presentation.
They have $$ operating into 2025, good news.
and, they made a first time presentation featuring the manufacturing upscaling of Pela , in anticipation of a phase 3 need.
Partnering was barely mentioned. not zero, but limited excitement in that leg.
Call me paranoid, it almost seemed like they were afraid of making certain statements.
Again could be an indication of on- going negotiations & N.D.A. Language...that has my hope.
What do the analysts think/ say?
RBC still holds by their Buy rating with a $6 target , and $18 upside assuming they start phase 3 and/ or get a partnership.
They do go on in th3 notes to include expectations of a partership announcement in this year ( 2024).
in the details they more or less replicated what mangement is saying.
starting phase 3 panc this year, updates on MBc this year.
while Onc did not mention partnership details the RBC analyst did.
So, moving forward....let's hope that comes soon.
one thing analysts will rarely do is discuss buyouts. There is no published data to comment about.
They by design are ultra conservative.
will be interesting to see what the other 4-5 analysts come up with.
great week all